Methods	Double blind, placebo controlled trial; 2 parallel groups.
	Unit of randomization: individual.
Participants	Dates of data collection: not reported.
	Setting: Athens, Greece.
	Inclusion criteria: women undergoing elective or non-elective CS. Age range 17-40 years Exclusion criteria: allergy to metronidazole, amnionitis, and pyrexia
Interventions	Metronidazole 500 mg IV 2 hours or immediately preoperatively, 500 mg intraopera-tively, 1000 mg 8 hours post-operatively (N = 50), vs placebo (N = 50)
Outcomes	Wound infection; endometritis; inadequate wound healing (metronidazole 1/50 vs placebo 8/50); mean temperature (36.8°C SD 1.02 vs 37.6, 1.03); duration of hospital stay.
Notes	Although the authors are not identical and the presentation of the data makes direct comparisons difficult, the description of the 2 studies cited is so similar that it is presumed the 2 citations refer to the same patient population
	Translated from Bulgarian.
	Class of antibiotic: nitroimidazole (metronidazole).
	Subgroups: both elective and non-elective CS; before cord clamping.
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	Women were divided into 2 groups; no further details available
Allocation concealment?	Unclear	No information provided.
Blinding?	Unclear	Placebo given to control group; described as “double blind”.
All outcomes
Incomplete outcome data addressed?	Unclear	No information available (pending full translation).
All outcomes
Free of selective reporting?	Unclear	Insufficient information to judge.
Free of other bias?	Unclear	There was no significant difference in parity and age between the groups. There was insufficient other information which to judge
Overall low risk of bias?	Unclear	Unclear.